In vivo evaluation of P-glycoprotein and breast cancer resistance protein modulation in the brain using [11C]gefitinib

Nuclear Medicine and Biology

Volumn 36, Issue 3, 2009, Pages 239-246

  Kawamura, Kazunori ^a   Yamasaki, Tomoteru ^a   Yui, Joji ^a   Hatori, Akiko ^a   Konno, Fujiko ^a   Kumata, Katsushi ^a   Irie, Toshiaki ^a   Fukumura, Toshimitsu ^a   Suzuki, Kazutoshi ^a   Kanno, Iwao ^a   Zhang, Ming Rong ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

11C Gefitinib; BCRP; Brain penetration; Cyclosporin A; GF120918; P gp

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CARBON 11; CYCLOSPORIN A; ELACRIDAR; GEFITINIB; GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CONTROLLED STUDY; DRUG STRUCTURE; EXPERIMENTAL MOUSE; IN VIVO STUDY; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; WILD TYPE;

ACRIDINES; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BRAIN; CARBON RADIOISOTOPES; MALE; MICE; NEOPLASM PROTEINS; P-GLYCOPROTEIN; POSITRON-EMISSION TOMOGRAPHY; QUINAZOLINES; RADIOACTIVITY; TETRAHYDROISOQUINOLINES;

EID: 62549091902     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2008.12.006     Document Type: Article

References (51)

1. Gottesman M.M., Fojo T., and Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2 (2002) 48-58
2. Borst P., and Oude Elferink R. Mammalian ABC transporters in health and disease. Annu Rev Biochem 71 (2002) 537-592
3. Doyle L.A., Yang W., Abruzzo L.V., et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 95 (1998) 15665-15670
4. Staud F., and Pavek P. Breast cancer resistance protein (BCRP/ABCG2). Int J Biochem Cell Biol 37 (2005) 720-725
5. Maliepaard M., Scheffer G.L., Faneyte I.F., van Gastelen M.A., Pijnenborg A.C., Schinkel A.H., et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61 (2001) 3458-3464
6. Jonker J.W., Buitelaar M., Wagenaar E., Van Der Valk M.A., Scheffer G.L., Scheper R.J., et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A 99 (2002) 15649-15654
7. Cooray H.C., Blackmore C.G., Maskell L., and Barrand M.A. Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 13 (2002) 2059-2063
8. Doyle L.A., and Ross D.D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22 (2003) 7340-7358
9. Mao Q., and Unadkat J.D. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J 7 (2005) E118-E133
10. Haimeur A., Conseil G., Deeley R.G., and Cole S.P. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab 5 (2004) 21-53
11. Breedveld P., Beijnen J.H., and Schellens J.H. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci 27 (2006) 17-24
12. Baselga J., and Averbuch S.D. ZD1839 ('Iressa') as an anticancer agent. Drugs 60 (2000) 33-40
13. Arteaga C.L., and Johnson D.H. Tyrosine kinase inhibitors-ZD1839 (Iressa). Curr Opin Oncol 13 (2001) 491-498
14. Özvegy-Laczka C., Hegedu{double acute}s T., Várady G., Ujhelly O., Schuetz J.D., Váradi A., et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 65 (2004) 1485-1495
15. Yanase K., Tsukahara S., Asada S., Ishikawa E., Imai Y., and Sugimoto Y. Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol Cancer Ther 3 (2004) 1119-1125
16. Nakamura Y., Oka M., Soda H., Shiozawa K., Yoshikawa M., Itoh A., et al. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res 65 (2005) 1541-1546
17. Hyafil F., Vergely C., Du Vignaud P., and Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53 (1993) 4595-4602
18. Dantzig A.H., Shepard R.L., Cao J., Law K.L., Ehlhardt W.J., Baughman T.M., et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 56 (1996) 4171-4179
19. Dale I.L., Tuffley W., Callaghan R., Holmes J.A., Martin K., Luscombe M., et al. Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative. Br J Cancer 78 (1998) 885-892
20. de Bruin M., Miyake K., Litman T., Robey R., and Bates S.E. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett 146 (1999) 117-126
21. Jonker J.W., Smit J.W., Brinkhuis R.F., Maliepaard M., Beijnen J.H., Schellens J.H., et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 92 (2000) 1651-1656
22. Allen J.D., van Loevezijn A., Lakhai J.M., van der Valk M., van Tellingen O., Reid G., et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 1 (2002) 417-425
23. Planting A.S., Sonneveld P., van der Gaast A., Sparreboom A., van der Burg M.E., Luyten G.P., et al. A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors. Cancer Chemother Pharmacol 55 (2005) 91-99
24. Kuppens I.E., Witteveen E.O., Jewell R.C., Radema S.A., Paul E.M., Mangum S.G., et al. A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. Clin Cancer Res 13 (2007) 3276-3285
25. Elsinga P.H., Hendrikse N.H., Bart J., Vaalburg W., and van Waarde A. PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. Curr Pharm Des 10 (2004) 1493-1503
26. Elsinga P.H., Hendrikse N.H., Bart J., van Waarde A., and Vaalburg W. Positron emission tomography studies on binding of central nervous system drugs and P-glycoprotein function in the rodent brain. Mol Imaging Biol 7 (2005) 37-44
27. Ishiwata K., Kawamura K., Yanai K., and Hendrikse N.H. In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically. J Nucl Med 48 (2007) 81-87
28. 11C-colchicine for PET imaging of multiple drug resistance. J Nucl Med 41 (2000) 493-501
29. Elsinga P.H., Franssen E.J., Hendrikse N.H., Fluks L., Weemaes A.M., van der Graaf W.T., et al. Carbon-11-labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PET. J Nucl Med 37 (1996) 1571-1575
30. 18F-paclitaxel in nonhuman primates. J Nucl Med 44 (2003) 1330-1339
31. 11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation. Nucl Med Biol 30 (2003) 747-751
32. Doze P., Van Waarde A., Elsinga P.H., Hendrikse N.H., and Vaalburg W. Enhanced cerebral uptake of receptor ligands by modulation of P-glycoprotein function in the blood-brain barrier. Synapse 36 (2000) 66-74
33. 11C]carvedilol reveals P-glycoprotein modulation kinetics. Br J Pharmacol 145 (2005) 1045-1051
34. 18F]MPPF in rats. Eur J Pharmacol 407 (2000) 273-280
35. 11C](R)-(-)-RWAY. Synapse 61 (2007) 96-105
36. 11C-Loperamide and its N-desmethyl radiometabolite are avid substrates for brain permeability-glycoprotein efflux. J Nucl Med 49 (2008) 649-656
37. Lewis J.S., Dearling J.L., Sosabowski J.K., Zweit J., Carnochan P., Kelland L.R., et al. Copper bis(diphosphine) complexes: radiopharmaceuticals for the detection of multi-drug resistance in tumours by PET. Eur J Nucl Med 27 (2000) 638-646
38. 64Cu-labeled monocationic copper(II) complex. Nucl Med Biol 29 (2002) 289-294
39. 68Ga radiopharmaceutical for SPECT and PET of MDR1 P-glycoprotein transport activity in vivo: validation in multidrug-resistant tumors and at the blood-brain barrier. J Nucl Med. 46 (2005) 354-364
40. Gilday J.P., and Moody D. Process for the preparation of 4-(3′-chlorp-4′-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy) quinazoline. PCT Int Appl (2004) A1 WO/2004/024703
41. Dodic N., Dumaitre B., Daugan A., and Pianetti P. Synthesis and activity against multidrug resistance in Chinese hamster ovary cells of new acridone-4-carboxamides. J Med Chem 38 (1995) 2418-2426
42. 11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase. Bioorg Med Chem Lett 16 15 (2006) 4102-4106
43. 11C]Ro15-1788. Appl Radiat Isot 36 (1985) 971-976
44. Jonker J.W., Freeman J., Bolscher E., Musters S., Alvi A., Titley I., et al. Contribution of the ABC transporters Bcrp1 and Mdr1a/1b to the side population phenotype in mammary gland and bone marrow of mice. Stem Cells 23 (2005) 1059-1065
45. Takei M., Kida T., and Suzuki K. Sensitive measurement of positron emitters eluted from HPLC. Appl Radiat Isot 55 (2001) 229-234
46. Pick A., Müller H., and Wiese M. Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2). Bioorg Med Chem 16 (2008) 8224-8236
47. de Vries N.A., Zhao J., Kroon E., Buckle T., Beijnen J.H., and van Tellingen O. P-Glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin Cancer Res 13 (2007) 6440-6449
48. Malingré M.M., Beijnen J.H., Rosing H., Koopman F.J., Jewell R.C., Paul E.M., et al. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br J Cancer 84 (2001) 42-47
49. 125I-Labeled human epidermal growth factor. Binding, internalization, and degradation in human fibroblasts. J Cell Biol 71 (1976) 159-171
50. Haigler H.T., McKanna J.A., and Cohen S. Direct visualization of the binding and internalization of a ferritin conjugate of epidermal growth factor in human carcinoma cells A-431. J Cell Biol 81 (1979) 382-395
51. Wiley H.S. Trafficking of the ErbB receptors and its influence on signaling. Exp Cell Res 284 (2003) 78-88